{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:35:58Z","timestamp":1793806558055,"version":"4.6.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00277-019-03625-x","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T02:12:53Z","timestamp":1552011173000},"page":"1071-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Thromboembolic events in polycythemia vera"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-7004","authenticated-orcid":false,"given":"Martin","family":"Griesshammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Besses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168:317\u2013325. \n                    https:\/\/doi.org\/10.7326\/M17-0028","journal-title":"Ann Intern Med"},{"key":"3625_CR2","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122:2176\u20132284. \n                    https:\/\/doi.org\/10.1182\/blood-2013-03-460154","journal-title":"Blood"},{"key":"3625_CR3","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"key":"3625_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124. \n                    https:\/\/doi.org\/10.1056\/NEJMoa035572","journal-title":"N Engl J Med"},{"key":"3625_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00277-018-3483-6","volume":"98","author":"K Wille","year":"2018","unstructured":"Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M (2018) High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 98:93\u2013100. \n                    https:\/\/doi.org\/10.1007\/s00277-018-3483-6","journal-title":"Ann Hematol"},{"key":"3625_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","unstructured":"Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 123:656\u2013664","journal-title":"Ann Intern Med"},{"key":"3625_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33:313\u2013320. \n                    https:\/\/doi.org\/10.1055\/s-2007-976165","journal-title":"Semin Thromb Hemost"},{"key":"3625_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11739-009-0319-3","volume":"5","author":"AM Vannucchi","year":"2010","unstructured":"Vannucchi AM (2010) Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med 5:177\u2013184. \n                    https:\/\/doi.org\/10.1007\/s11739-009-0319-3","journal-title":"Intern Emerg Med"},{"key":"3625_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18. \n                    https:\/\/doi.org\/10.1186\/s13045-016-0242-9","journal-title":"J Hematol Oncol"},{"key":"3625_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.clml.2018.08.009","volume":"18","author":"MR Grunwald","year":"2018","unstructured":"Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, Colucci P, Mesa R (2018) Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk 18:788\u2013795.e2. \n                    https:\/\/doi.org\/10.1016\/j.clml.2018.08.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3625_CR11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","volume":"7","author":"S Cerquozzi","year":"2017","unstructured":"Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A (2017) Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J 7:662. \n                    https:\/\/doi.org\/10.1038\/s41408-017-0035-6","journal-title":"Blood Cancer J"},{"key":"3625_CR12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A (2014) In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124:3021\u20133023. \n                    https:\/\/doi.org\/10.1182\/blood-2014-07-591610","journal-title":"Blood"},{"key":"3625_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, de Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, CYTO-PV Collaborative Group (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"key":"3625_CR14","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, M\u00fcllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874\u20131881. \n                    https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"key":"3625_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057\u20131069. \n                    https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"key":"3625_CR16","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446\u20132452. \n                    https:\/\/doi.org\/10.1182\/blood-2006-08-042515","journal-title":"Blood"},{"key":"3625_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S et al (2019) A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol 184:176\u2013191. \n                    https:\/\/doi.org\/10.1111\/bjh.15648","journal-title":"Br J Haematol"},{"key":"3625_CR18","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1002\/ajh.24583","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A (2017) The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol 92:E5\u2013E6. \n                    https:\/\/doi.org\/10.1002\/ajh.24583","journal-title":"Am J Hematol"},{"key":"3625_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/asheducation-2009.1.629","volume":"2009","author":"MF McMullin","year":"2009","unstructured":"McMullin MF (2009) Idiopathic erythrocytosis: a disappearing entity. Hematology Am Soc Hematol Educ Program 2009:629\u2013635. \n                    https:\/\/doi.org\/10.1182\/asheducation-2009.1.629","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3625_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3324\/haematol.2009.008417","volume":"95","author":"SK Braekkan","year":"2010","unstructured":"Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB (2010) Hematocrit and risk of venous thromboembolism in a general population. The Troms\u00f8 study. Haematologica 95:270\u2013275. \n                    https:\/\/doi.org\/10.3324\/haematol.2009.008417","journal-title":"Haematologica"},{"key":"3625_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3233\/CH-2011-1455","volume":"49","author":"T Gori","year":"2011","unstructured":"Gori T (2011) Viscosity, platelet activation, and hematocrit: progress in understanding their relationship with clinical and subclinical vascular disease. Clin Hemorheol Microcirc 49:37\u201342. \n                    https:\/\/doi.org\/10.3233\/CH-2011-1455","journal-title":"Clin Hemorheol Microcirc"},{"key":"3625_CR22","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1161\/01.CIR.87.6.1915","volume":"87","author":"GD Lowe","year":"1993","unstructured":"Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E (1993) Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh artery Study. Circulation 87:1915\u20131920","journal-title":"Circulation"},{"key":"3625_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","volume":"2","author":"TC Pearson","year":"1978","unstructured":"Pearson TC, Wetherley-Mein G (1978) Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 2:1219\u20131222","journal-title":"Lancet"},{"key":"3625_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V64.1.1.1","volume":"64","author":"AI Schafer","year":"1984","unstructured":"Schafer AI (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1\u201312","journal-title":"Blood"},{"issue":"Suppl 5","key":"3625_CR25","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C, ESMO Guidelines Committee (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v85\u2013v99. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv203","journal-title":"Ann Oncol"},{"key":"3625_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138:354\u2013358. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06674.x","journal-title":"Br J Haematol"},{"key":"3625_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V Stefano De","year":"2010","unstructured":"De Stefano V, Za T, Rossi E et al (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85:97\u2013100. \n                    https:\/\/doi.org\/10.1002\/ajh.21593","journal-title":"Am J Hematol"},{"key":"3625_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","volume":"126","author":"T Barbui","year":"2015","unstructured":"Barbui T, Masciulli A, Marfisi MR, Tognoni G, Finazzi G, Rambaldi A, Vannucchi A (2015) White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126:560\u2013561. \n                    https:\/\/doi.org\/10.1182\/blood-2015-04-638593","journal-title":"Blood"},{"key":"3625_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.thromres.2015.02.023","volume":"135","author":"Y Lim","year":"2015","unstructured":"Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, Bang SM (2015) Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res 135:846\u2013851. \n                    https:\/\/doi.org\/10.1016\/j.thromres.2015.02.023","journal-title":"Thromb Res"},{"key":"3625_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","volume":"12","author":"K Martin","year":"2017","unstructured":"Martin K (2017) Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep 12:389\u2013396. \n                    https:\/\/doi.org\/10.1007\/s11899-017-0400-3","journal-title":"Curr Hematol Malig Rep"},{"key":"3625_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/asheducation-2007.1.363","volume":"2007","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Barbui T (2007) Thrombocytosis and thrombosis. Hematology Am Soc Hematol Educ Program 2007:363\u2013370. \n                    https:\/\/doi.org\/10.1182\/asheducation-2007.1.363","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3625_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/asheducation-2005.1.201","volume":"2005","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Green AR (2005) Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2005:201\u2013208. \n                    https:\/\/doi.org\/10.1182\/asheducation-2005.1.201","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3625_CR33","first-page":"172","volume":"23","author":"AP Tartaglia","year":"1986","unstructured":"Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172\u2013176","journal-title":"Semin Hematol"},{"key":"3625_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2012-02-366054","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F (2012) How I treat polycythemia vera. Blood 120:275\u2013284. \n                    https:\/\/doi.org\/10.1182\/blood-2012-02-366054","journal-title":"Blood"},{"key":"3625_CR35","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larran","year":"2012","unstructured":"Alvarez-Larran A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernandez-Boluda JC, Ferrer-Marin F, Angona A, Gomez M, Muina B, Guillen H, Teruel A, Bellosillo B, Burgaleta C, Vicente V, Besses C (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119:1363\u20131369. \n                    https:\/\/doi.org\/10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"key":"3625_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3324\/haematol.2009.011866","volume":"95","author":"P Quist-Paulsen","year":"2010","unstructured":"Quist-Paulsen P, Naess IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, Hammerstrom J (2010) Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 95:119\u2013125. \n                    https:\/\/doi.org\/10.3324\/haematol.2009.011866","journal-title":"Haematologica"},{"key":"3625_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A, on behalf of the AGIMM and IIC Investigators (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96:315\u2013318. \n                    https:\/\/doi.org\/10.3324\/haematol.2010.031070","journal-title":"Haematologica"},{"key":"3625_CR38","doi-asserted-by":"publisher","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952\u20131959. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404854","DOI":"10.1038\/sj.leu.2404854"},{"key":"3625_CR39","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3324\/haematol.2017.182303","volume":"103","author":"M Brusson","year":"2018","unstructured":"Brusson M, De Grandis M, Cochet S et al (2018) Impact of hydroxycarbamide and interferon-alpha on red cell adhesion and membrane protein expression in polycythemia vera. Haematologica 103:972\u2013981. \n                    https:\/\/doi.org\/10.3324\/haematol.2017.182303","journal-title":"Haematologica"},{"key":"3625_CR40","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1055\/s-0038-1667015","volume":"118","author":"A Guadall","year":"2018","unstructured":"Guadall A, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, el Nemer W, Cassinat B, Kiladjian JJ (2018) Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features. Thromb Haemost 118:1586\u20131599. \n                    https:\/\/doi.org\/10.1055\/s-0038-1667015","journal-title":"Thromb Haemost"},{"key":"3625_CR41","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907\u20133913. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.36.0792","journal-title":"J Clin Oncol"},{"key":"3625_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-018-0048-9","volume":"8","author":"V Stefano De","year":"2018","unstructured":"De Stefano V, Carobbio A, Di Lazzaro V et al (2018) Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J 8:25. \n                    https:\/\/doi.org\/10.1038\/s41408-018-0048-9","journal-title":"Blood Cancer J"},{"key":"3625_CR43","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","volume":"94","author":"JC Hernandez-Boluda","year":"2015","unstructured":"Hernandez-Boluda JC, Arellano-Rodrigo E, Cervantes F et al (2015) Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 94:911\u2013918. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2330-2","journal-title":"Ann Hematol"},{"key":"3625_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Za T, Rossi E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93:372\u2013380. \n                    https:\/\/doi.org\/10.3324\/haematol.12053","journal-title":"Haematologica"},{"key":"3625_CR45","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2016.85","volume":"30","author":"V Stefano De","year":"2016","unstructured":"De Stefano V, Ruggeri M, Cervantes F et al (2016) High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 30:2032\u20132038. \n                    https:\/\/doi.org\/10.1038\/leu.2016.85","journal-title":"Leukemia"},{"key":"3625_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3324\/haematol.2016.152769","volume":"102","author":"A Alvarez-Larran","year":"2017","unstructured":"Alvarez-Larran A, Perez-Encinas M, Ferrer-Marin F et al (2017) Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 102:103\u2013109. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.152769","journal-title":"Haematologica"},{"key":"3625_CR47","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.3324\/haematol.2017.165126","volume":"102","author":"T Barbui","year":"2017","unstructured":"Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM, Grant from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milano) Special Program Molecular Clinical Oncology 5x1000 to AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) (2017) No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials. Haematologica 102:e219\u2013e221. \n                    https:\/\/doi.org\/10.3324\/haematol.2017.165126","journal-title":"Haematologica"},{"key":"3625_CR48","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","volume":"90","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90:3370\u20133377","journal-title":"Blood"},{"key":"3625_CR49","first-page":"167","volume":"23","author":"ME Kaplan","year":"1986","unstructured":"Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR (1986) Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 23:167\u2013171","journal-title":"Semin Hematol"},{"key":"3625_CR50","first-page":"145","volume-title":"Neoplastic diseases of the blood","author":"MAHB Dawson","year":"2012","unstructured":"Dawson MAHB (2012) The pathogenesis, diagnosis, and treatment of polycythemia vera. In: Wiernik P (ed) Neoplastic diseases of the blood. Springer-Verlag, New York, pp 145\u2013146"},{"key":"3625_CR51","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.24851","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol 92:1131\u20131136. \n                    https:\/\/doi.org\/10.1002\/ajh.24851","journal-title":"Am J Hematol"},{"key":"3625_CR52","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172:786\u2013793. \n                    https:\/\/doi.org\/10.1111\/bjh.13886","journal-title":"Br J Haematol"},{"key":"3625_CR53","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113:4829\u20134833. \n                    https:\/\/doi.org\/10.1182\/blood-2008-09-176818","journal-title":"Blood"},{"key":"3625_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt J, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33\u201345. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043800","journal-title":"N Engl J Med"},{"key":"3625_CR55","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cncr.26194","volume":"118","author":"R Latagliata","year":"2012","unstructured":"Latagliata R, Spadea A, Cedrone M, di Giandomenico J, de Muro M, Villiv\u00e0 N, Breccia M, Anaclerico B, Porrini R, Spirito F, Rago A, Avvisati G, Alimena G, Montanaro M, Andriani A, and Gruppo Laziale SMPC Ph1 neg (2012) Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 118:404\u2013409. \n                    https:\/\/doi.org\/10.1002\/cncr.26194","journal-title":"Cancer"},{"key":"3625_CR56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L, Finazzi MC, Rumi E, Martinelli V, Vianelli N, Luigia Randi M, Bertozzi I, de Stefano V, Za T, Rossi E, Ruggeri M, Elli E, Cacciola R, Cacciola E, Pogliani E, Rodeghiero F, Baccarani M, Passamonti F, Finazzi G, Rambaldi A, Bosi A, Cazzola M, Barbui T, Vannucchi AM, On behalf of the AGIMM Investigators (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 87:552\u2013554. \n                    https:\/\/doi.org\/10.1002\/ajh.23160","journal-title":"Am J Hematol"},{"key":"3625_CR57","unstructured":"Stegelmann F, Wille K, Schauer S et al (2017) Hydroxyurea is associated with skin toxicity in myeloproliferative neoplasms: results from a prospective non-interventional study. EHA Abstracts E1335. \n                    https:\/\/learningcenter.ehaweb.org\/eha\/2017\/22nd\/181111\/frank.stegelmann.hydroxyurea.is.associated.with.skin.toxicity.in.html\n                    \n                  . Accessed 15 Aug 2018"},{"key":"3625_CR58","first-page":"4208","volume":"130","author":"C Besses","year":"2017","unstructured":"Besses C, Garcia-Pallarols F, Angona A et al (2017) Hydroxyurea mucocutaneous toxicity: a prospective cohort study of 110 ET and PV patients from a single institution. Blood 130:4208","journal-title":"Blood"},{"key":"3625_CR59","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065\u20133072. \n                    https:\/\/doi.org\/10.1182\/blood-2008-03-143537","journal-title":"Blood"},{"key":"3625_CR60","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418\u20135424. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.6075","journal-title":"J Clin Oncol"},{"key":"3625_CR61","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/leu.2015.326","volume":"30","author":"JJ Kiladjian","year":"2016","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B (2016) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30:776\u2013781. \n                    https:\/\/doi.org\/10.1038\/leu.2015.326","journal-title":"Leukemia"},{"key":"3625_CR62","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3109\/10428194.2014.893310","volume":"55","author":"M Sever","year":"2014","unstructured":"Sever M, Newberry KJ, Verstovsek S (2014) Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory\/resistant to hydroxyurea. Leuk Lymphoma 55:2685\u20132690. \n                    https:\/\/doi.org\/10.3109\/10428194.2014.893310","journal-title":"Leuk Lymphoma"},{"key":"3625_CR63","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.leukres.2014.06.019","volume":"38","author":"BT Huang","year":"2014","unstructured":"Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL (2014) Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res 38:1177\u20131183. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2014.06.019","journal-title":"Leuk Res"},{"key":"3625_CR64","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R (2015) Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126:1762\u20131769. \n                    https:\/\/doi.org\/10.1182\/blood-2015-04-637280","journal-title":"Blood"},{"key":"3625_CR65","doi-asserted-by":"crossref","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2016) Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients. Blood 128(1 suppl) [abstract 475]","DOI":"10.1182\/blood.V128.22.475.475"},{"key":"3625_CR66","unstructured":"Kiladjian JJ, Cassinat B, Soret-Dulphy J et al (2017) Molecular response to hydroxyurea and ropeginterferon alfa-2B in the PROUD-PV randomized phase 3 trial. EHA Abstracts S787. \n                    https:\/\/learningcenter.ehaweb.org\/eha\/2017\/22nd\/182074\/jean-jacques.kiladjian.molecular.response.to.hydroxyurea.and.ropeginterferon.html\n                    \n                  . Accessed 15 Aug 2018"},{"key":"3625_CR67","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2017) Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial. Blood 130(1 suppl) [abstract 320]"},{"key":"3625_CR68","unstructured":"Jakavi (ruxolitinib) (2016) [summary of product characteristics] Novartis Europharm Limited: Horsham, UK"},{"key":"3625_CR69","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372:426\u2013435. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"3625_CR70","doi-asserted-by":"publisher","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18:88\u201399. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30558-7","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"3625_CR71","unstructured":"Kiladjian J-J, Verstovsek S, Griesshammer M et al (2017) Results from the 208-week (4-year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV). Blood 130(1 suppl) [abstract 322]"},{"key":"3625_CR72","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/bjh.14764","volume":"182","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ (2018) Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol 182:279\u2013284. \n                    https:\/\/doi.org\/10.1111\/bjh.14764","journal-title":"Br J Haematol"},{"key":"3625_CR73","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","volume":"97","author":"M Griesshammer","year":"2018","unstructured":"Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F (2018) Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol 97:1591\u20131600. \n                    https:\/\/doi.org\/10.1007\/s00277-018-3365-y","journal-title":"Ann Hematol"},{"key":"3625_CR74","doi-asserted-by":"crossref","unstructured":"Miller CB, Kiladjian J, Griesshammer M, Naim A, Sun W, Gadbaw B, Verstovsek S, Vannucchi AM (2015) The effect of ruxolitinib on white blood cell counts in patients with polycythemia vera: results from the RESPONSE trial. Blood 126(1 suppl) [abstract 4070]","DOI":"10.1182\/blood.V126.23.4070.4070"},{"key":"3625_CR75","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","volume":"27","author":"BT Samuelson","year":"2016","unstructured":"Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D (2016) The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis 27:648\u2013652. \n                    https:\/\/doi.org\/10.1097\/MBC.0000000000000446","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3625_CR76","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ (2016) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80 week follow up from the RESPONSE trial. Haematologica 101:821\u2013829. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.143644","journal-title":"Haematologica"},{"issue":"7","key":"3625_CR77","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V (2018) Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood 132(7):694\u2013706. \n                    https:\/\/doi.org\/10.1182\/blood-2017-10-810739","journal-title":"Blood"},{"key":"3625_CR78","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1160\/th15-04-0326","volume":"115","author":"V Stefano De","year":"2016","unstructured":"De Stefano V, Qi X, Betti S, Rossi E (2016) Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 115:240\u2013249. \n                    https:\/\/doi.org\/10.1160\/TH15-04-0326","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"3625_CR79","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.thromres.2012.08.259","volume":"130","author":"N Riva","year":"2012","unstructured":"Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 130(Suppl 1):S1\u2013S3. \n                    https:\/\/doi.org\/10.1016\/j.thromres.2012.08.259","journal-title":"Thromb Res"},{"key":"3625_CR80","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","volume":"8","author":"G Finazzi","year":"2018","unstructured":"Finazzi G, De Stefano V, Barbui T (2018) Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J 8:64. \n                    https:\/\/doi.org\/10.1038\/s41408-018-0100-9","journal-title":"Blood Cancer J"},{"key":"3625_CR81","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"111","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cervantes F, Leebeek FW et al (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111:4922\u20134929. \n                    https:\/\/doi.org\/10.1182\/blood-2007-11-125328","journal-title":"Blood"},{"key":"3625_CR82","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921\u20134928. \n                    https:\/\/doi.org\/10.1182\/blood-2011-09-376517","journal-title":"Blood"},{"issue":"1","key":"3625_CR83","first-page":"555578","volume":"2","author":"V Perifanis","year":"2018","unstructured":"Perifanis V, Neokleous N, Protopappas A, Kaiafa G, Savopoulos C (2018) Splanchnic vein thrombosis: risk factors, clinical presentation, diagnosis, treatment. Blood Res Transfus J 2(1):555578 \n                    https:\/\/juniperpublishers.com\/oabtj\/OABTJ.MS.ID.555578.php","journal-title":"Blood Res Transfus J"},{"key":"3625_CR84","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1038\/bcj.2016.103","volume":"6","author":"V Stefano De","year":"2016","unstructured":"De Stefano V, Vannucchi AM, Ruggeri M et al (2016) Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J 6:e493. \n                    https:\/\/doi.org\/10.1038\/bcj.2016.103","journal-title":"Blood Cancer J"},{"key":"3625_CR85","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cncr.22026","volume":"107","author":"RT Silver","year":"2006","unstructured":"Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451\u2013458. \n                    https:\/\/doi.org\/10.1002\/cncr.22026","journal-title":"Cancer"},{"key":"3625_CR86","doi-asserted-by":"publisher","unstructured":"Kiladjian J, Zach\u00e9e P, Hino M et al (2018) Long-term efficacy and safety (5 years) in RESPONSE, a phase 3 study comparing ruxolitinib (RUX) with best available therapy (BAT) in hydroxyurea (HU)-resistant\/intolerant patients (pts) with polycythemia vera (PV). Blood 132(1 suppl) [abstract 1753]. \n                    https:\/\/doi.org\/10.1182\/blood-2018-99-115129","DOI":"10.1182\/blood-2018-99-115129"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03625-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03625-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03625-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T19:10:14Z","timestamp":1583521814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03625-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03625-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735288334.793583124","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"19 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Martin Griesshammer has received consultancy fees and honoraria from and has served on speakers bureaus for Gilead, Baxalta, AOP Orphan, Shire, and Novartis and has received honoraria from and has served on speakers bureaus for Sanofi. Jean-Jacques Kiladjian has received honoraria from and has participated in advisory boards for Novartis, AOP Orphan, and Celgene. Carlos Besses has received consultancy fees and honoraria from Novartis and has received research support from Novartis and Celgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}